JeanMarie Guenot holds a Ph. D and has over two decades of experience within biotechnology and the pharmaceutical industry. She has specific expertise in the building and rebuilding companies, in addition to working in both the public and private sector. JeanMarie is both the President and CEO of Amphivena Therapeutics, Incorporated. Amphivena focuses on development of antibody therapies that treat hematologic malignancies. Before she became President and CEO of Amphivena, Dr. JeanMarie Guenot developed and ran SKS Ocular. While at SKS Ocular, she developed technologies and therapeutics for glaucoma, ocular inflammation, and other eye-related health issues. All of which is available on her Facebook page: https://www.facebook.com/jeanmarie.guenot.9
In addition to being a success in the field of biotechnology, Dr. Guenot has managed venture capital investments at Atlas Venture. A fine business leader with a keen sense for the aggressive development of needed biotechnology treatments, JeanMarie Guenot also has a solid foundation as a scientist. She led an 800 million dollar transaction, involving Biogen Idec-PDL 50:50, which she co-developed and co-commercialized. During her collegiate studies, she focused on Chemistry, with an emphasis on protein structure prediction, drug design, and methods for molecular dynamics. She developed drugs for autoimmune diseases, and inflammation while working at Preclinical R&D at Hoffmann-La Roche. Her Guenot LLC bio shows Jeanmarie earned a Ph.D. from the University of California, San Francisco and an MBA from The Wharton School at the University of Pennsylvania.
Amphivena Therapeutics Incorporated, based in San Francisco, California, is a developer of immunotherapies for cancer. The company’s leading drug treatments focus on acute myeloid leukemia, also known as AML. Constantly making advances in medicine, in August 2016, the FDA accepted an investigational new drug application from Amphivena, known as AMV564. A clinical study focused on AMV564 will research the safety of, in addition to the necessary doses for treating patients with AML. Apmhivena and its progress in biotechnology and pharmaceutical developments have been reported by outlets, such as MarketWired and Yahoo! Finance.